Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(148)
•••
Post by StockReddyon Mar 23, 2020 1:42pm
96 Views
Post# 30838380

Liminal BioSciences comments on Coronavirus (COVID-19)

Liminal BioSciences comments on Coronavirus (COVID-19)
"We are reviewing our own research conducted on plasminogen and other plasma-derived product candidates to determine if there are any further steps that we could be taking towards evaluating the potential benefit to COVID-19 patients," added Mr. Galbraith. "Given the global healthcare emergency and that these activities are outside our current focus, we expect to coordinate further actions, if any, with other researchers, government departments, regulatory authorities and non-profit agencies, all of whom continue searching in an integrated manner for potentially effective treatments and vaccines."

https://stockhouse.com/news/press-releases/2020/03/22/liminal-biosciences-comments-on-coronavirus-covid-19
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities